MG
BBIO icon

Marex Group’s BridgeBio Pharma BBIO Stock Holding History

Marex Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$859K Buy
11,535
+6,675
+137% +$468K ﹤0.01% 540
2026
Q1 		$361K Buy
+4,860
New +$352K ﹤0.01% 713
2025
Q3 		– Sell
-6,328
Closed -$273K – 862
2025
Q2 		$273K Buy
+6,328
New +$230K ﹤0.01% 468

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marex Group's BBIO Position: Q2 2026 in Review

Marex Group increased its BridgeBio Pharma (BBIO) stake by 137% in Q2 2026, buying an estimated $468K and bringing the position to 11,535 shares worth $859K. The position accounts for ﹤0.01% of the portfolio, ranked #540.

Marex Group first reported a position in BBIO in Q2 2025 and has held it in 3 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Marex Group held 11,535 shares of BridgeBio Pharma worth $859K as of Q2 2026.
  • Marex Group bought 6,675 BridgeBio Pharma shares in Q2 2026, an estimated $468K.
  • BridgeBio Pharma made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #540 holding.
  • Marex Group first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 3 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.